[Individual monitoring of thiopurine and methotrexate treatment].
Baslund
Bo
B
H:S Rigshospitalet, Reumatologisk Klinik, Klinisk Farmakologisk Afdeling. baslund@rh.hosp.dk
Dalhoff
Kim P
KP
Schmiegelow
Kjeld
K
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use; D016903:Drug Monitoring; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use; D015122:Mercaptopurine / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use; D008727:Methotrexate / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic
D000964:Antimetabolites, Antineoplastic; D007166:Immunosuppressive Agents; D015122:Mercaptopurine; D008727:Methotrexate